Kyungdong Pharmaceutical announced on the 17th that its consolidated sales in the first half of this year were 87.4 billion won, an increase of regarding 7% compared to the same period of the previous year. During the same period, operating profit was 5.5 billion won and net profit was 2 billion won.
In the first half of the year, separate sales were 85.5 billion won, operating profit was 5.8 billion won, and net profit was 2.7 billion won.
The top-line growth is attributable to the normalization of business centered on local hospitals and hospitals following the lifting of social distancing, and brisk sales of ETC related to respiratory diseases. However, operating profit decreased due to increased R&D and investment costs to secure growth engines.
A company official said, “The sales of prescription drugs increased due to the increase in treatment and prescriptions following the lifting of the distance and strengthening face-to-face sales to local hospitals.” VALUE’ capsule-type red ginseng also supported sales growth.”
He added, “We are managing factors that increase manufacturing cost, such as rising raw materials and subsidiary materials, by preemptively securing raw materials and improving production efficiency.” .
[이 상 규 매경닷컴 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
ⓒ MBN (Daily Broadcasting) Unauthorized reproduction and redistribution prohibited
<!– 타불라 2018-03-06
타불라 2018-03-06 –>
- popular video
- attention
Please enable JavaScript to write comments in the library.